Claudio Santos is the Chief Executive Officer of Gyala Therapeutics, having collaborated with Invivo Partners and the Hospital Clinic de Barcelona to start the company.
Previously, he was Director of Business Development of Bioncotech Therapeutics and Director of Strategic Planning of Adorx Therapeutics (a cancer immunotherapy company which has signed a strategic collaboration agreement with Johnson & Johnson).
He has also worked in the venture capital industry as an Associate in the oncology-focused CRT Pioneer Fund, where he played a key role in investments in Achilles Therapeutics, Artios Pharma, Neophore Ltd and the Ras Inhibitors Programme. He led the Business Development activities of the later, which led to the signing of a collaboration and licensing agreement with Novartis. Before, he was a technology transfer manager at Cancer Research Technology (UK), where he was part of the team that licensed the PRMT5 project to MSD in a deal valued at up to $500m.
He received his PhD in Microbiology and Genetics from the University of Salamanca, and carried out postdoctoral research at the Cancer Research UK London Institute.